Insulin resistance, a new target for nitric oxide‐delivery drugs
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
In the Western hemisphere, the incidence of insulin resistance and its complications has been growing rapidly and is reaching epidemic proportions. Over the past decade, evidence has accumulated, indicating that nitric oxide (NO) plays a key role in the regulation of metabolic and cardiovascular homeostasis. Defective endothelial nitric oxide synthase (eNOS) driven NO synthesis causes insulin resistance, arterial hypertension and dyslipidemia in mice, and characterizes insulin‐resistant humans. On the other hand, stimulation of inducible nitric oxide synthase (iNOS) and NO overproduction in mice, may also cause metabolic insulin resistance, suggesting a Yin–Yang effect of NO in the regulation of glucose homeostasis. Here, we will review the evidence for this novel concept, and thereby provide the conceptual framework for the use of NO‐delivery drugs and pharmacological agents that modulate the bioavailability of endogenously produced NO for the treatment of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypertension in mice lacking the gene for endothelial nitric oxide synthase
Huang, P. L., Huang, Z., Mashimo, H., Bloch, K. D., Moskowitz, M. A., Bevan, J. A., & Fishman, M. C. (1995) · Nature · doi:10.1038/377239a0 · Cited by 2,070
Kern, P. A., Saghizadeh, M., Ong, J. M., Bosch, R. J., Deem, R., & Simsolo, R. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117899 · Cited by 1,305
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
Physiology of Nitric Oxide in Skeletal Muscle
Stamler, J. S., & Meissner, G. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.209 · Cited by 1,080
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035
Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J., & Ignarro, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260203 · Cited by 1,006
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114644 · Cited by 930
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Zeng, G., Nystrom, F. H., Ravichandran, L. V., Cong, L.-N., Kirby, M., Mostowski, H., & Quon, M. J. (2000) · Circulation · doi:10.1161/01.cir.101.13.1539 · Cited by 745
Zeng, G., & Quon, M. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118871 · Cited by 726
Cited by
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Nitric Oxide as a Unique Bioactive Signaling Messenger in Physiology and Pathophysiology
Tuteja, N., Chandra, M., Tuteja, R., & Misra, M. K. (2004) · BioMed Research International · doi:10.1155/s1110724304402034 · Cited by 269
“Cook and Scherrer [50] reviewed the evidence for this novel concept and provided the conceptual framework for the use of NO-delivery drugs and pharmacological agents that modulate the bioavailability of endogenously produced NO for the treatment of insulin resistance.”
BackgroundAyala, J. E., Bracy, D. P., Julien, B. M., Rottman, J. N., Fueger, P. T., & Wasserman, D. H. (2007) · Diabetes · doi:10.2337/db06-0883 · Cited by 237
“Several studies have shown that nitric oxide (NO) plays a key role in mediating the metabolic effects of insulin, including stimulation of muscle glucose uptake (2).”
BackgroundClustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice
Egli, M., Vollenweider, P., Burcelin, R., Nicod, P., & Thorens, B. (2003) · Swiss Medical Weekly · doi:10.4414/smw.2003.10239 · Cited by 161
“We speculate that a defect in nitric oxide synthesis may trigger many of the abnormalities making up the metabolic syndrome in humans, which thereby may represent a new target for pharmacological agents that deliver and/or modulate the bioavailability of endogenously produced nitric oxide [ 13 ].”
BackgroundAbudukadier, A., Fujita, Y., Obara, A., Ohashi, A., Fukushima, T., Sato, Y., Ogura, M., Nakamura, Y., Fujimoto, S., Hosokawa, M., et al. (2013) · Diabetes · doi:10.2337/db12-1242 · Cited by 52
“Similarly to several NO donors and NO moderating compounds (42), BH4 might also exert an insulin-sensitizing effect by augmenting the delivery of insulin and glucose to skeletal muscle via capillary recruitment.”
Metadata
- Authors
- Cook, S., & Scherrer, U.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2002-12
- Volume
- 16
- Issue
- 6
- Pages
- 441-453
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2126061278
- Cited by
- 44
- References
- 23
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin resistance, a new target for nitric oxide‐delivery drugs. https://app.cochat.ai/papers/10.1046/j.1472-8206.2002.00130.x
- The paper
- Cook, S., & Scherrer, U. (2002). Insulin resistance, a new target for nitric oxide‐delivery drugs. Fundamental & Clinical Pharmacology. https://doi.org/10.1046/j.1472-8206.2002.00130.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.